Literature DB >> 11577489

Nausea, vomiting, and retching: complex problems in palliative care.

V A Rhodes1, R W McDaniel.   

Abstract

Patients with advanced cancer commonly experience nausea, vomiting, and/or retching (NVR) as a result of the malignant process and its treatment. Recently, increasing attention is being focused on end-of-life care, which includes relief or reduction of symptoms such as NVR. Pre-chemotherapy preparation and patient education in the palliative care setting are essential to preventing acute and delayed distress from NVR, as well as anticipatory symptoms. Careful assessment of chemotherapy-related symptoms should distinguish between the three phenomena rather than taking a global approach. Strategies for preventing anticipatory nausea, for instance, may differ significantly from those designed to reduce frequency of vomiting. Management of anticancer treatment-related NVR should incorporate both pharmacologic and nonpharmacologic approaches, whenever appropriate, with the overall goal of improving and/or maintaining the patient's quality of life.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577489     DOI: 10.3322/canjclin.51.4.232

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  22 in total

Review 1.  The detoxification limitation hypothesis: where did it come from and where is it going?

Authors:  Karen J Marsh; Ian R Wallis; Rose L Andrew; William J Foley
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

Review 2.  Nausea and vomiting.

Authors:  Christopher O'Brien
Journal:  Can Fam Physician       Date:  2008-06       Impact factor: 3.275

Review 3.  Droperidol for treatment of nausea and vomiting in palliative care patients.

Authors:  Jemma Storrar; Morwenna Hitchens; Tracey Platt; Saskie Dorman
Journal:  Cochrane Database Syst Rev       Date:  2014-11-27

4.  Nausea and vomiting in palliative care.

Authors:  Charlotte Leach
Journal:  Clin Med (Lond)       Date:  2019-07       Impact factor: 2.659

5.  Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.

Authors:  Chi-Ting Liau; Nei-Min Chu; Hsueh-Erh Liu; Robert Deuson; Jade Lien; Jen-Shi Chen
Journal:  Support Care Cancer       Date:  2005-03-16       Impact factor: 3.603

6.  Sequence variants of the HTR3A gene contribute to the genetic prediction of postoperative nausea in Taiwan.

Authors:  Yi-Mei Joy Lin; Cheng-Da Hsu; Hsiao-Yen Hsieh; Chia-Chih Alex Tseng; H Sunny Sun
Journal:  J Hum Genet       Date:  2014-10-23       Impact factor: 3.172

Review 7.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

Review 8.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Virtual reality: a distraction intervention for chemotherapy.

Authors:  Susan M Schneider; Linda E Hood
Journal:  Oncol Nurs Forum       Date:  2007-01       Impact factor: 2.172

10.  Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting.

Authors:  Jing-Yu Tan; Lorna K P Suen; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-04-02       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.